KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.
Access
info:eu-repo/semantics/closedAccessDate
2023Author
Lavie, DavidTimmerman, John
Sanz, Ramon Garcia
Kim, Won Seog
Kim, Tae Min
Avigdor, Abraham
Dierickx, Daan
Jagadeesh, Deepa
Herrera, Alex Francisco
Metadata
Show full item recordCitation
Lavie, D., Timmerman, J., Sanz, R. G., Kim, W.S., Kim, T. M., Avigdor, A. ... Herrera, A. F. (2023). KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL, 02-06 June, 2023.Abstract
...
WoS Q Kategorisi
Q1Source
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)Volume
41Issue
16Collections
- Bildiri Koleksiyonu [516]
- WoS İndeksli Yayınlar Koleksiyonu [6585]